Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222050 | 0.84 | MAPT (0.60) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL3772532 | 0.80 | RORC (0.66) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL21174073 | 0.79 | NPC1 (0.61) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10802219 | 0.78 | RORC (0.63) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL223464 | 0.75 | MAPT (0.62) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL20578739 | 0.75 | ALDH1A1 (0.57) | MAPTNPC1RAB9A | |
| SCHEMBL16253024 | 0.74 | RORC (0.59) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL892695 | 0.74 | SMN1; SMN2 (0.58) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL10518851 | 0.74 | PARP1 (0.53) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL13901730 | 0.74 | NPC1 (0.90) | MAPTSMN1; SMN2RORCNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP11, MMP13, MMP14 | MAPT 4194/4885SMN1; SMN2 1265/4885RORC 3699/4885 |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | MAPT 4420/4885SMN1; SMN2 1734/4885RORC 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.